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Background: Multiple sclerosis (MS) is a chronic, progressive autoimmune disease 
of the central nervous system in which inflammation plays a key role in the induction, 
development, and progression. Most of the MS patients present with relapsing–remitting 
(RR) form, characterized by flare-ups followed by periods of recovery. Many inflammatory 
and anti-inflammatory cytokines have been proposed as backers in MS pathogenesis, 
and the balance between these differing cytokines can regulate MS severity. Interferon 
(IFN)-β, a current disease-modifying therapy for MS, has demonstrated beneficial 
effects in reducing disease severity in MS patients. However, its immunoregulatory and 
anti- inflammatory actions in MS are not wholly understood. The aim of the study was 
to define, in clinically stable patients with RR-MS, the serum concentration of several 
cytokines, canonical or not, and their modulation by IFN-β therapy.
Methods: Relapsing–remitting-MS patients were enrolled and diagnosed according to 
revised Mc Donald Diagnostic Criteria. A set of cytokines [including non-canonical neu-
rotransmitter acetylcholine (ACh) and adipokines] and B-cell differentiation molecules, as 
potential biomarkers, were evaluated in 30 non-treated RR-MS patients compared to 30 
IFN-β-treated MS patients and 30 age, gender, and body mass index-matched healthy 
controls (HC).
results: Naïve MS patients showed significantly higher levels of interleukin (IL)-1β, IL-12/
IL-23p40, IL-18, high-mobility group box protein-1, and IL-18 binding protein (IL-18BP) 
than MS-treated patients (p <  0.001 for all) and HC (p <  0.01). IFN-β therapy has 
significantly downmodulated IL-1β, IL-12/IL-23p40, IL-18 to normal levels (p < 0.001), 
whereas it has decreased IL-18BP (p < 0.001). ACh was significantly higher in the IFN-
β-treated than HC and non-treated MS patients (p < 0.001). No significant differences 
were observed either in adipokines concentration or in B-cell-associated molecules 
among the three study groups.
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inTrODUcTiOn
Many diseases of the central nervous system (CNS) show neuro-
inflammation as a common feature. Inflammatory reactions are 
necessary steps for removing invading agents, removing damaged 
cells, and helping tissue repair. However, uncontrolled neuroin-
flammation may lead to further tissue injury resulting in neural 
dysfunction or loss of function. The cross talk between periphery 
and CNS is crucial for the development of multiple sclerosis 
(MS), and understanding the complex network of signals may 
help to clarify its pathogenesis.
Multiple sclerosis is a CNS heterogeneous disease character-
ized by neuroinflammatory and neurodegenerative processes 
linked to the activation of autoimmune T cells, macrophages, and 
microglia that lead to immune responses potentiated by cytokines’ 
storm initiated by a positive feedback loop between immune cells 
and pro-inflammatory cytokines. Immune responses may be 
propagated within the CNS by infiltrating immune cells activated 
in the periphery that have crossed the blood–brain barrier (BBB) 
by adhesion to the endothelial cells and by the cytokines secreted 
by immune cells that may have direct neurotoxic properties.
Inflammasome is multiprotein intracellular complex receptors 
and sensors of stressors, which activates highly inflammatory 
signaling pathways, crucial for host defense, but whose dys-
regulation can in turn cause autoinflammatory and autoimmune 
disorders (1). NOD-like receptor family, pyrin domain contain-
ing 3 (NLRP3) inflammasome is considered a key contributor to 
the development of neuroinflammation and may be activated by 
different stimuli such as microbes, aggregated and misfolded pro-
teins, and adenosine triphosphate, driving activation of caspase-1, 
and processing of interleukin (IL)-1β and IL-18, which mediate 
subsequent cascade immune responses (2). In experimental 
autoimmune encephalomyelitis (EAE), NLRP3 inflammasome 
induces demyelination and disease progression by promoting 
chemotactic migration of T helper cells, and antigen-presenting 
cells into the CNS (3, 4).
Interleukin-1β and IL-18 drive inflammatory responses 
through diverse downstream signaling pathways, leading to 
neuronal damage. IL-1β stimulates the activation of microglia 
and astrocytes, driving T  cells infiltration within the CNS and 
inducing the production of pro-inflammatory cytokines, such as 
IL-6 and tumor necrosis factor (TNF)-α (5). IL-18 induces the 
production of adhesion molecules, pro-inflammatory cytokines, 
and chemokines in natural killer cells, T helper 1 (Th1), and B cells 
(6, 7), activates signaling pathways in microglia, and increases cas-
pase-1 expression and pro-inflammatory cytokine production (8).
The role of B cells in MS pathology other than the production 
of pathogenic autoantibodies (9) has been related to activation 
and regulation of T cells and supported by the presence of B cells 
in MS lesions. Recently, it was suggested that cytokine production 
by B cells might be an important factor in autoimmune disease 
pathogenesis. In fact, B cells express TNF-β and interferon (IFN)-γ 
that promote Th1 differentiation (10), promote macrophage acti-
vation (11), and induce also production of IL-6, which in turn 
triggers EAE pathogenesis through activation of Th17 cells (12).
Both T and B cells and macrophages express components of 
cholinergic system, known as the non-neural cholinergic system, 
involved in the modulation of acetylcholine (ACh) directly pro-
duced by immune system cells (13). In several autoimmune and/
or inflammatory diseases, the cholinergic anti-inflammatory sys-
tem plays a central role in the immunological homeostasis (14).
Acetylcholine is a classical neurotransmitter of the central and 
peripheral nervous systems, and non-neuronal cells, including 
immune cells, can also produce and release ACh (15). The non-
neuronal ACh acting through autocrine and paracrine routes may 
modulate inflammatory responses. At present, while it is known 
that ACh modulates production of IL-2 in T cells and TNF-α in 
macrophages, little is known about the effects exerted by ACh on 
dendritic cells (DCs) and B cells, other than induction of Ca2 + 
signaling in B cells (16).
Clinical, experimental, and epidemiological studies, showing 
that pro-inflammatory mediators maintain microenvironmental 
conditions that promote loss of immune self-tolerance, have sug-
gested the involvement of adipokines that may link the immune 
system with metabolic status in the pathogenesis of MS (17). 
Contrary to the chronic inflammatory aspect of MS, it is not 
fully explored whether and how adipokine levels are altered in 
MS patients. In fact, a pro-inflammatory environment present in 
MS could affect adipokine levels as well as T regulatory (Treg) 
functions.
Interferon-β is a first-line immunomodulatory treatment in 
relapsing–remitting (RR)-MS and shows beneficial effects on dis-
ease progression reducing the frequency and severity of clinical 
exacerbations (18). Its mechanisms of action include modulatory 
effects on costimulatory molecules (19) and shift from Th1 to Th2 
cytokine production (20–26), and other studies have suggested 
modulation of Th17 development (27–29).
The protective mechanisms of IFN-β are complex and have 
not been completely unveiled and their failure on many patients 
has not been explained (30, 31). In this context, we propose to 
shift the attention from the brain to the role of the circulating 
cytokines (including non-canonical neurotransmitter ACh and 
adipokines) and B-cell differentiation molecules in MS patients. 
Thus, this study was carried out to evaluate whether IFN-β 
treatment may alter the circulating levels of cytokines resulting 
by inflammasome activation, B  cells activation, and specific 
conclusion: Although more experimental evidence are required, we speculate that the 
efficacy of treatment of MS with IFN-β is mediated, at least in part, by its ability to work 
on several levels to slow down the disease progression. Proposed actions include the 
modulation of IL-1–inflammasome axis and modulation of ACh, B-cell activating factor/a 
proliferation-inducing ligand system, and several adipokines.
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TaBle 1 | Demographic and clinical data of patients with RR-MS and HC.
rr-Ms hc (n = 30) p-Value
iFn-β treatment 
(n = 30)
Untreated 
(n = 30)
Age (years) 43.0 (36.0–54.8) 51.0 (39.0–59.5) 47.0 (36.0–54.0) 0.300a
Gender, n (%) 0.585b
Male 12 (40.0) 10 (33.3) 11 (36.7)
Female 18 (60.0) 20 (66.7) 19 (63.3)
EDSS score 1.5 (1.5–2.7) 2.0 (1.0–3.4) – 0.634c
Disease  
duration (years)
6.0 (4.0–14.0) 4.0 (2.0–8.0) – 0.071c
OCB 7.0 (3.0–12.7) 8.0 (3.5–11.0) – 0.998c
Data are expressed as median and IQR.
aKruskal–Wallis H test.
bChi-square test.
cMann–Whitney U test.
EDSS, Expanded Disability Status Scale; OCB, oligoclonal bands; HC, healthy controls; 
RR-MS, relapsing–remitting multiple sclerosis; IFN, interferon; IQR, interquartile range.
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adipokines’ levels, to denote a novel mechanism of action for this 
immunomodulatory agent.
MaTerials anD MeThODs
clinical–Demographic Details of Ms 
Patients and healthy controls (hc)
The present clinical cohort is part of a large effort on investi-
gating genetic and immunological associations in MS. For this 
study, 30 HC (19 women and 11 men, median age 47 years) and 
60 RR-MS patients diagnosed according to the revised McDonald 
diagnostic criteria (32, 33) were recruited from the Neurological 
Clinic, Department of Clinical and Experimental Medicine, 
University of Pisa and Hospital Gregorio Marañón in Madrid. 
The ethics com mittee of the institutions approved the protocol, 
and all patients gave  their written informed consent for study 
inclusion, and the study was conducted in accordance with the 
ethical guidelines of the 2013 Declaration of Helsinki. The clinical 
form of RR-MS was determined according to the classification of 
Lublin and Reingold (34).
Inclusion criteria were as follows: age ≥ 18 years old; diagnosis 
of RR-MS with absence of clinical relapses at least 1 month before 
the inclusion in the study, and ability to provide a valid written 
informed consent. All subjects included had negative blood tests 
for other autoimmune or infectious diseases.
At the time of sampling, 30 RR-MS patients (20 women and 
10 men, median age 51 years) were untreated and 30 RR-MS (18 
women and 12 men, median age 43 years) were on daily subcuta-
neous IFN-β therapy (12 million IUs) for more than 1 year at the 
time of inclusion in the study. All patients were between 36 and 
55 years and were ambulatory. For each patient, the estimation of 
disease, concomitant illnesses, and family history, and a detailed 
neurological examination were performed to determine the 
patients’ level of disability according to the Expanded Disability 
Status Scale (EDSS) (33).
Exclusion criteria were active infection or inflammation of 
any kind, and current or recent treatment with corticosteroids or 
any other immunomodulatory therapy during the last 6 months 
before inclusion in the study. Patients with relapses treated with 
corticosteroids within 1 month preceding enrollment were also 
excluded from the study.
After basic anthropometric measurements such as weight, 
height, and calculation of body mass index (BMI), all patients 
and the HC were classified as normal weight (NW). HC were 
frequency matched for age, gender, and BMI with MS patients 
and selected among the general population within the same 
geographical areas as MS patients. Samples were collected at the 
same time to diminish bias associated with the circadian cycles. 
Demographic and clinical data of the samples from the patients 
with RR-MS are presented in Table 1.
serum samples collection
Blood samples (3–5 mL) were collected at least 24 h after the last 
IFN-β injection, from peripheral veins according to the routine 
puncture method. Serum was collected by blood centrifugation 
at 2,000 x g for 15 min and frozen at −80°C within 30 min, until 
assayed.
Determination of cytokine levels
Determination of serum levels of the cytokines TNF-α, IL-1β, 
IL-12/23p40, IL-18, IL-18 binding protein (IL-18BP), and 
transforming growth factor (TGF)-β1 was performed using 
commercial ELISA Kits (R&D Systems Quantikine TM, 
Minneapolis, MN, USA). The specificity and the sensitivity for 
the cytokines were defined according to the manufacturer’s 
instructions. Minimum detectable dose (MDD) was 1.6  pg/
mL for TNF-α, 1 pg/mL for IL-1β, <15 pg/μL for IL-12/23p40, 
12.5  pg/mL for IL-18, 2.25  pg/mL for IL-18BP, and 15.4  pg/
mL for TGF-β1. Total levels of high-mobility group box 
protein-1 (HMGB-1) were measured in duplicate using an 
available commercial ELISA kit (Elabscience Biotechnology, 
Wuhan, PRC) according to the manufacturer’s instructions 
(MDD = 18.75 pg/mL). IL-37 (MDD = 10 pg/mL) was measured 
in duplicate using an available commercial ELISA kit (Boster 
Bio. Tech., Pleasanton, CA, USA). Apelin-36 (MDD = 0.01 ng/
mL), retinol-binding protein 4 (RBP-4) (MDD  =  0.1  ng/
mL), and Visfatin-C (MDD =  0.1  ng/mL) were measured in 
duplicate using an available commercial ELISA kit (Phoenix 
Pharm., Burlingame, CA, USA). Paired samples were measured 
simultaneously on the same plate, and samples with coefficients 
of variation higher than 10% were repeated.
Quantification of serum B-cell activating 
Factor (BaFF), BaFF receptor (BaFFr), 
and a Proliferation-inducing ligand 
(aPril)
All ELISA reagents were provided by Boster Bio. Tech. 
(Pleasanton, CA, USA). MDD was 2 pg for BAFF, 10 pg/mL for 
APRIL, and 10 pg/mL for BAFFR. Briefly, samples were added 
in duplicate on precoated plates. Next, biotinylated detection 
antibody was added, and samples were incubated with strepta-
vidin-conjugated horseradish peroxidase for 30  min at room 
temperature. The plate was read at 450 nm. Standard curve was 
generated using known concentrations of recombinant analyte 
included in each run.
FigUre 1 | Box–whisker graphs of cytokine levels in the three study groups. Box–whisker plots show the 25th and 75th percentile range (box) with Tukey 95% 
confidence intervals (whiskers) and median values (transverse lines in the box). +++p < 0.001 interferon (IFN)-β-treated vs untreated; ooop < 0.001, oop < 0.01 
untreated vs healthy controls (HC); and *p < 0.05 IFN-β-treated vs HC of post hoc analysis. p-Value reported in figures are relative to Kruskal–Wallis H test.
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Measurement of ach levels
Acetylcholine was measured by commercial colorimetric/fluori-
metric kit (Abcam, Cambridge, UK). The level of Ch/ACh (pmol/
well) was calculated by plotting the fluorescence of each sample 
in relation to choline standard curve. The measurement of the 
fluorescence was obtained using Glomax Multi Detection System 
(Promega, MI, Italy) at λ Ex/Em 535/587 nm.
statistical analysis
The quantitative variables were summarized as median and 
interquartile range (IQR) according to their distribution and 
qualitative variables as frequency and percentage. A Shapiro–
Wilk’s test was performed to evaluate the departures from normal 
distribution for each variable.
Kruskal–Wallis H Test was performed to evaluate differences 
in quantitative variables among HC, treated, and untreated 
RR-MS patients. Mann–Whitney U test was performed to evalu-
ate differences between treated and untreated RR-MS patients.
To evaluate cytokine profile changes in patients with different 
EDSS scores, patients were divided on bases of median EDSS 
score of each group (1.5 for IFN-β-treated group and 2.0 for 
untreated group) in two subgroups, i.e., patients with high or low 
EDSS score.
Cross-tabulation analyses were conducted to assess the rela-
tionship between qualitative variables. Pearson Chi-Square test 
was performed to assess the statistical significance of observed 
relationships. Non-parametric Spearman’s correlation coefficients 
(Rho) were calculated to evaluate the correlation between cytokines, 
separately in IFN-β treated or non-treated RR-MS patients.
For all analyses, a post hoc test, a priori defined, was applied 
with Dunn–Sidak method adjustment for multiple comparisons. 
All statistical tests were evaluated at an alpha level of 0.05. 
Statistical analysis was performed using IBM® SPSS Statistics v 
20.0 software (SPSS Inc., Chicago, IL, USA).
resUlTs
il-1 Family and inflammasome-Dependent 
Proteins
30 newly diagnosed RR-MS subjects without medication were 
enrolled to evaluate the serum levels of several pro-inflammatory 
cytokines. The results obtained showed a statistically significant 
elevation of serum levels of IL-1β, IL-18, and IL-12/23p40 in 
untreated MS patients with respect to IFN-β treated and HC 
(Figures 1 and 2). Given that the activity of IL-18 is balanced by 
the presence of a high affinity, naturally occurring IL-18BP, a good 
estimation of IL-18 activity can be provided by the simultaneous 
detection of both IL-18 and IL-18BP. We observed an imbalance 
of IL-18 to IL-18BP with a higher IL-18BP/IL-18 ratio in RR-MS 
patients than in HC (1.2 vs 0.85, respectively). Also, the serum 
levels of HMGB-1 were significantly higher in the untreated 
RR-MS group compared to HC (31%).
Interferon-β was the most widely used therapy to treat relaps-
ing forms of MS, albeit their specific functions are still unmet 
knowledge and biomarkers for therapeutic effects remain to be 
identified. Thus, we have analyzed which cytokines, among those 
increased in serum of MS patients, may be modulated by IFN-β 
treatment. We have found substantially lower levels of IL-1β, 
FigUre 2 | Box–whisker graphs of interleukin (IL)-18 and IL-18 binding protein (IL-18BP) levels in the three study groups. Box–whisker plots show the 25th and 
75th percentile range (box) with Tukey 95% confidence intervals (whiskers) and median values (transverse lines in the box). +++p < 0.001 interferon (IFN)-β-treated vs 
untreated; op < 0.05 untreated vs healthy controls (HC); and **p < 0.01, ***p < 0.001 IFN-β-treated vs HC of post hoc analysis. p-Value reported in figures are 
relative to Kruskal–Wallis H test.
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IL-12/23p40, TNF-α, and HMGB-1 in serum of MS patients 
undergoing IFN-β treatment than in serum of naïve RR-MS 
patients. According to these results, IFN-β-treated MS patients 
showed also lower IL-18 levels, while IL-18BP levels were higher 
than those in untreated patients (Figures 1 and 2).
Interleukin-37 is considered a natural suppressor of innate 
immunity included in the IL-1 family and was placed in the 
portfolio of classical anti-inflammatory cytokines such as 
TGF-β (35). In our cohort of IFN-β-treated patients, serum 
levels of IL-37 appeared as an increasing trend compared 
to untreated patients [3.38 (IQR: 2.51–4.68) vs 3.04 (IQR: 
2.59–6.01)] and the same relationship was found for TGF-β1 
[27,871.75 (IQR: 22,672.83−32,873.73) vs 21985.20 (IQR: 
19,425.04–33,815.69)].
non-traditional cytokines
In this study, levels of ACh were confirmed to be lower also in 
new recruited RR-MS patients without medication than in HC. 
Significantly elevated levels of RBP-4 were found in serum of 
RR-MS patients, compared to HC subjects (p < 0.027). Visfatin-C 
and Apelin-36 showed non-significantly higher levels in RR-MS 
patients compared to HC, but untreated RR-MS patients with 
EDSS < 2 showed higher levels of Visfatin.
To explore whether the IFN-β treatment influences these 
mediators of neural-immune and metabolic circuits, we 
evaluated the levels of adipokines and ACh in serum of IFN-β-
treated RR-MS patients. No significant differences of Visfatin, 
Apelin-36, and adiponectin were detected in the IFN-β therapy 
group compared to the non-treated group. RBP-4 was found to 
be lower in the IFN-β therapy group and significantly higher in 
untreated RR-MS in comparison with the HC group (Figure 3). 
ACh levels were significantly increased under IFN-β therapy 
in comparison with the HC and the untreated RR-MS groups 
(Figure 4).
correlation Between cytokines in iFn- 
β-Treated or non-Treated rr-Ms Patients
In our untreated patients, correlation analyses assessing associa-
tions of adipokines with IL-1β showed positive correlation with 
Apelin-36 levels (Rho = 0.525, p = 0.031) and negative correlation 
with Visfatin-C (Rho = −0.521, p = 0.050). RPB-4 negatively cor-
related with IL-12/23p40 (Rho = −0.700, p = 0.004).
On the other hand, IFN-β-treated patients showed a significant 
positive correlation between IL-18 and IL-18BP (Rho =  0.648, 
p = 0.043); and IL-18 and IL-12/23p40 (Rho = 0.683, p = 0.042).
iFn-β Therapy and BaFF/aPril system
The BAFF/APRIL system includes two ligands, BAFF of the TNF-
family and APRIL, and the BAFFR, which is crucial for B  cell 
homeostasis. To understand whether this system is affected by 
IFN-β, we have compared their serum levels in untreated and 
IFN-β-treated RR-MS patients (Table  2). In our IFN-β-treated 
RR-MS patients, we have detected a slight increase in APRIL 
serum levels with respect to non-treated patients (68.0 vs 50.7, 
p  =  0.537). In addition, most patients under IFN-β therapy 
released more BAFF compared to non-treated RR-MS patients 
(415.6 vs 400.4, p = 0.662) (Table 3).
cytokine Profile analysis Based on eDss
Expanded Disability Status Scale was used to quantify and moni-
tor changes in the disability in MS, by classifying MS patients 
into two groups: (1) representing MS patients without disability 
(EDSS  ≤  1.5, for IFN-β-treatment group and EDSS  ≤  2 for 
untreated group) and (2) including MS patients with varying 
degrees of disability (EDSS > 1.5 for IFN-β-treatment group and 
EDSS > 2 for untreated group). Since EDSS correlates with the 
degree of neurological dysfunction (mainly motor), potentially 
related to the neuroinflammation, we sought to determine whether 
cytokine levels vary in patients with different EDSS scores. 
Importantly, IL-1β, TNF-α, IL-18, IL-37, TGF-β1, RBP-4, BAFF, 
APRIL, and BAFFR had higher levels, while IL-18BP, IL-12/23p40, 
HMGB-1, and Visfatin-C had lower values in untreated patients 
with EDSS > 2 compared to patients with EDSS ≤ 2. In the IFN-β-
treated group, IL-1β and IL-12/23p40, IL-37, TGF-β1, Apelin-36, 
BAFF, and BAFFR levels were higher in patients with EDSS > 1.5 
than in patients with EDSS ≤ 1.5, while IL-18, IL-18BP, RBP-4, 
HMGB-1, and APRIL were lower in patients with EDSS > 1.5. 
Our results suggest that IL-1β, IL-18, IL-18BP, and IL-12/23p40 
play a role in MS pathogenesis and course, since they are specifi-
cally modulated by IFN-β treatment (Table 2).
FigUre 3 | Box–whisker graphs of adipokine levels in the three study groups. Box–whisker plots show the 25th and 75th percentile range (box) with Tukey 95% 
confidence intervals (whiskers) and median values (transverse lines in the box). op < 0.05 untreated vs healthy controls (HC). p-Value reported in figures are relative 
to Kruskal–Wallis H test.
FigUre 4 | Acetylcholine (Ach) levels (pmol/mL) in the three study groups. 
Box–whisker plots show the 25th and 75th percentile range (box) with Tukey 
95% confidence intervals (whiskers) and median values (transverse lines in 
the box). ++p < 0.01 IFN-β-treated vs untreated; **p < 0.01 IFN-β-treated vs 
healthy controls (HC) post hoc analysis. p-Value reported in figures are 
relative to the Kruskal–Wallis H test.
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DiscUssiOn
Multiple sclerosis is characterized by neuroinflammatory, auto-
immune, and neurodegenerative processes both directly and 
indirectly linked to an inappropriate activation of the immune 
system against CNS “self ” antigens. Neuroinflammation is known 
to directly and systemically contribute to the recruitment of 
peripheral inflammatory cells and their products within the CNS 
and to increase BBB permeability. Bidirectional communication 
between the brain and the peripheral immune system has been 
well described (36–38), and dysfunction of the BBB, responsible 
for extensive migration of lymphocytes into the CNS, is considered 
a hallmark of the MS. The subsequent activation of autoreactive 
T cells within the CNS, resident microglia and macrophages, would 
trigger a strong immune response characterized by the secretion of 
chemokines, cytokines, and growth factors (39) among other events, 
further causing myelin, axonal, neuronal, and collateral CNS dam-
age (40). The dysfunction of endogenous or exogenous immune 
cells and their products may be accountable of inflammation-
mediated neurodegeneration. The two major endogenous cells in 
the CNS that drive inflammation are astrocytes and mononuclear 
phagocytes, which include microglia and perivascular macrophages 
(41). Cytokines produced in periphery can signal the CNS via 
humoral and neuronal routes. In general, actions occurring either 
in periphery or within the CNS that are related to immune activa-
tion and inflammation display a similar pattern. Understanding the 
intricate networks of signals pointing out the cross talk between 
the immune system and CNS in response to different stimuli is 
one of the main ways of elucidating the pathogenesis of MS and 
detecting possible targets for more specific therapy. On the basis 
of these premises, we carried out an observational cross-sectional 
study in RR-MS patients by simultaneously studying immune and 
nervous biomarkers that could offer a more integrated view of MS 
pathophysiology and of IFN-β effects.
TaBle 3 | Median and interquartile range of selected mediators.
rr-Ms p-Valuea
iFn-β treatment (n = 30) Untreated (n = 30)
APRIL (pg/mL) 68.0 (44.5–100.5) 50.7 (39.4–78.4) 0.537
BAFF (pg/mL) 415.6 (230.7–792.3) 400.4 (221.6–504.9) 0.622
BAFFR (pg/mL) 27.9 (23.3–30.4) 29.8 (25.0–36.3) 0.429
ap-Value relative to Mann–Whitney U test between groups.
IFN, interferon; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; 
BAFFR, BAFF receptor; RR-MS, relapsing–remitting multiple sclerosis.
TaBle 2 | Median and interquartile range of selected mediators.
iFn-β treatment Untreated
eDss ≤ 1.5 eDss > 1.5 eDss ≤ 2.0 eDss > 2.0
IL-18 (pg/mL) 46.1 (17.8; 98.1) 43.7 (38.5; 58.9) 386.6 (363.1; 447.4) 406.7 (306.2; 452.3)
IL-18BP (pg/mL) 6,710.6 (3,132.4; 9,091.3) 5,753.9 (4,310.8; 8,870.0) 500.2 (376.6; 603.5) 430.5 (354.8; 524.9)
TNF-α (pg/mL) 2.3 (2.0; 2.6) 2.2 (2.1; 2.4) 2.9 (2.4; 3.5) 3.7 (3.0; 4.3)
IL-1β (pg/mL) 14.9 (12.9; 19.4) 17.6 (15.0; 21.9) 87.3 (82.0; 91.4) 89.3 (78.0; 91.2)
IL-12/23p40 (pg/mL) 30.4 (25.5; 36.2) 38.7 (26.3; 52.3) 342.4 (251.6; 438.3) 314.8 (188.3; 404.2)
RBP-4 (ng/mL) 9,661.3 (3,033.9; 14,073.5) 4,354.5 (1,948.1; 7,696.0) 1,123.9 (944.3; 1,123.9) 3,333.5 (1,372.5; 3,333.5)
Visfatin-C (ng/mL) 4.0 (3.1; 6.8) 4.2 (4.1; 8.6) 15.8 (4.7; 15.8) 6.9 (6.3; 6.9)
Apelin-36 (ng/mL) 2.8 (2.6; 4.2) 3.7 (1.3; 5.5) 2.4 (1.8; 3.2) 3.0 (2.3; 3.0)
HMGB-1 (ng/mL) 920.5 (832.3; 978.4) 797.1 (628.9; 871.0)* 969.6 (905.9; 1,063.0) 839.5 (659.2; 930.2)°
HMW (ng/mL) 6,701.1 (3,855.6; 6,701.1) 9,626.8 (4,784.6; 9,626.8) 9,817.9 (6,590.3; 9,934.7) 7,565.7 (6,950.1; 7,565.7)
IL-37 (pg/mL) 3.4 (2.2; 3.4) 5.1 (4.1; 5.7)* 2.4 (2.2; 2.9) 4.4 (2.9; 6.2)°
TGF-β1 (pg/mL) 22,672.8 (18,058.2; 28,222.9) 29,893.6 (27,149.7; 38,249.9)* 33,891.2 (26,870.7; 38,354.9) 38,585.9 (29,054.2; 43,153.9)°
BAFFR (pg/mL) 22.5 (20.8; 22.5) 32.7 (22.4; 38.7) 23.2 (20.7; 26.2) 31.9 (27.5; 37.5)
APRIL (pg/mL) 52.2 (38.5; 52.2) 46.6 (35.2; 57.2) 43.9 (35.2; 52.3) 51.1 (38.8; 91.9)
BAFF (pg/mL) 615.1 (251.0; 615.1) 730.0 (430.0; 825.0) 87.9 (63.2; 95.8) 411.8 (366.5; 545.8)°
*p < 0.05 EDSS ≤ 1.5 vs EDSS > 1.5; °p < 0.05 EDSS ≤ 2.0 vs EDSS > 2.0 post hoc analysis.
IFN, interferon; RR-MS, relapsing–remitting multiple sclerosis; IL, interleukin; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth factor-β1; HMGB-1, high-mobility group 
box protein-1; RBP-4, retinol-binding protein 4; BAFF, B-cell activating factor; BAFFR, BAFF receptor; APRIL, a proliferation-inducing ligand; IL-18BP, IL-18 binding protein.
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Activation of inflammasome directly produces various regula-
tory or pathogenic actions in cells or tissues such as pyroptosis 
(42, 43), interference with cellular cytoskeleton arrangement (44), 
alteration in cell membrane permeability (45), and enhanced 
lipid metabolism (46), although the induction of classical 
inflammatory response is the main action. In MS patients, the 
inflammasome differently regulates cytokine expression. In fact, 
the level of mRNA expression of genes such as IL-18, IL-1β, IL-1 
receptor antagonist, NACHT, LRR, and PYD domain-containing 
protein 3 (NALP3), and caspase1 is upregulated in PBMCs from 
RR-MS patients in comparison with healthy donors (47). Studies 
addressing serum profiles of cytokines that are essential to initi-
ate key immune responses and maintenance of the inflammatory 
milieu in MS patients are limited and often contradictory. Thus, 
in this study, we have analyzed different groups of cytokines, 
adipokines, ACh neurotransmitter, and B-cell differentiation 
molecules to better understand their networks in naive RR-MS 
patients compared to IFN-β-treated MS patients and HC.
NACHT, LRR and PYD domain-containing protein 3 inflam-
masome, besides regulating the release of caspase activation-
dependent cytokines IL-1β and IL-18, is also implicated in the 
production of the HMGB-1. Our data confirm the involvement 
of pro-inflammatory mediators, such as TNF-α, IL-1β, IL-18, and 
HMGB-1, matured by NALP3 inflammasome, but also IL-18BP, 
IL-12/23, in the pathophysiology and clinical course of MS (48). 
In fact, the capability to activate inflammasome by different 
adjuvants in experimental MS models drives the occurrence of 
the disease (49). In addition, our results showed significantly 
higher serum levels of HMGB-1 in the RR-MS group compared to 
HC (31%), pointing to a putative role for this inflammatory-like 
cytokine in RR-MS pathogenesis.
In our RR-MS patients, the mean serum levels of IL-37 were 
influenced by disease severity. This suggests that IL-37 may be part 
of a feedback loop to control underlying inflammation in MS patho-
genesis. The management of IL-18 signaling requires the presence 
of its soluble inhibitor IL-18BP, and excessive IL-18BP concentra-
tions may limit the unpleasant effects of the non-mitigated IL-18, 
either by postponing signaling until appropriate conditions are 
met or by the eventual degradation or elimination of the protein 
complex. Several diseases show that an elevation of IL-18BP was 
in response to increased IL-18. It is interesting to note that a com-
plex of IL-37 and IL-18BP was found to inhibit the production of 
IL-18-dependent IFN-γ of about 30% more than IL-18BP alone 
(50). Experimental conditions indicate that IL-37, which signals 
through IL-18 receptor-α and orphan receptor SIGIRR/IL-1R8 
(51), may contribute to IL-18 inhibition. Currently, the in  vivo 
impact of IL-37 on IL-18BP inhibition is unknown. Therefore, our 
results may help to clarify their role in MS disease.
The source of HMGB-1 in MS patients’ serum may be hetero-
geneous, from injured neurons and astrocytes and from immune-
activated cells. By evaluating serum HMGB-1 in MS patients, 
we observed decreased levels in IFN-β-treated MS patients and 
a correlation between serum HMGB-1 and indicators of MS 
disease severity. Our results are consistent with earlier studies 
showing that higher serum HMGB-1 levels in MS patients may 
play a pathogenetic role and suggesting that modulation of serum 
HMGB-1 could be related to the clinical improvement associated 
with IFN-β in MS patients (52).
Previous studies showed that ACh inhibits IL-1β, IL-18, 
and HMGB-1 release by suppression of inflammasome activity 
(53, 54). In a previous study, we have reported that RR-MS 
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patients have lower ACh and higher IL-1β and IL-17 levels in 
both CSF and serum compared to healthy subjects (53).
Acetylcholine and adipokines behave as hormones participat-
ing in neurotransmission and mediation of metabolic processes, 
respectively, and can modulate innate and adaptive immune 
cells. The involvement of the cholinergic system in memory and 
learning functions is clinically evident in neurodegenerative 
disease. The diminished synthesis of ACh can contribute to 
memory and cognitive function impairment, these are common 
clinical manifestations in MS patients. Recent studies have shown 
the involvement of ACh and adipokines in the pathogenesis of 
immune-mediated diseases, such as MS (53, 55). A previous study 
has suggested that inhibition of ACh-esterase (AChE) activity 
may have a positive effect in the treatment of MS (56, 57), and 
Mazzanti et al. have shown that IFN-β reduces AChE activity in 
different brain structures from rats experimentally demyelinated 
by ethidium bromide (58) improving the hypothesis that ACh 
modulates the inflammatory process (14).
Our results reinforce the previous observation that a reduction 
in ACh levels is involved in RR-MS and that ACh and circulating 
cytokines are mutually influenced (59). Thus, another mechanism 
for beneficial effect of IFN-β in the modulation of inflammatory 
cytokines may be the restoration of ACh levels.
Several authors have shown that in MS patients, significantly 
lower adiponectin and higher leptin correlated with disease dis-
ability (EDSS) and may represent a marker of clinical disease activ-
ity (60). Inflammatory and immunologic mechanisms in obesity 
might potentially explain the association between increased risk 
of MS and adolescent obesity (55, 61). In our cohort of RR-MS 
patients, we have observed an increased trend of several adipokines, 
also in relation with EDSS score. Vitamin A plays important roles 
in immunological responses and brain development, in MS could 
decrease inflammation and increase tolerance to autoantigens, and 
may also help in brain protection. RBP-4 is the specific transporter 
protein of vitamin A, and a correlation between RBP-4 levels and 
increased BMI was reported. Our cohort of RR-MS patients, all 
classified as NW subjects, showed higher serum levels of RBP-4 
than those in HC and were related to EDSS score.
Visfatin activates NLRP3 inflammasome in endothelial cells via 
ROS-dependent mechanism (62) inducing inter-endothelial junc-
tion disruption and is primarily associated with release by endothe-
lial cells. Serum levels of Visfatin-C were higher in our cohort of 
RR-MS patients than in HC. In contrast, HMGB-1 was significantly 
downmodulated in MS patients. This ubiquitous nuclear and cyto-
solic protein is released during sterile inflammation and infection 
by immune cells, or passively by damaged or necrotic cells, into 
the extracellular space. Outside the cell, HMGB-1 activates the 
immune system acting as a chemokine or an alarmin to mediate 
physiological and pathological responses, such as autoimmunity. 
Previous studies have demonstrated HMGB-1 can initiate cellular 
responses primarily by interacting with cell surface receptor for 
advanced glycation end products and toll-like receptor 4 leading 
to inflammation, immunity, chemotaxis, and other cell processes 
(63). On the other hand, adiponectin is an adipocytokine that 
may contribute to the onset of Alzheimer’s disease (AD) and all-
cause dementia (64). Depending on the presence of adiponectin 
receptors in neurological tissue, the relationship between plasma 
adiponectin and dementia is still controversial (65–68), and a 
correlation between serum levels of adiponectin and severity of 
dementia in NW AD subjects has been reported (69). Several stud-
ies reported that upregulation of Visfatin can influence regulation 
of cytokine secretion and macrophage and neutrophil activation 
(70). Our data show an increased trend of adipokines’ levels related 
to EDSS and stress the association between adipocytokines and 
MS independently from obesity. Thus, we speculate that high levels 
of adipokines could in turn enhance pro-inflammatory cytokine 
secretion favoring MS development and chronicity and represent 
a link among inflammation, autoimmunity, and breakdown of 
homeostasis. Additional prospective studies with a higher cohort 
size with MS are required to confirm this hypothesis.
The BAFF/APRIL system is involved in B cell survival, differ-
entiation and class switching, and in size of the peripheral B cell 
pool. BAFF is the main regulated element of the BAFF/APRIL 
system, and its serum concentrations were elevated in the majority 
of our IFN-β-treated MS patients and were associated with more 
severe clinical disease, whereas the opposite trend was observed 
for BAFFR. Since B cells can exert both detrimental and beneficial 
effects, additional evaluation of BAFF/APRIL system is needed.
Understanding the cross talk between the immune and nerv-
ous systems and how it can be modulated is necessary for the 
treatment of neurological diseases such as MS, and our data 
wedge in the complex mosaic of the mechanisms underlying 
the control of inflammatory reaction. Taken together, the results 
from the present study point to the role of several canonical and 
non-canonical cytokines in MS pathophysiology and course and 
their variation in response to IFN-β treatment.
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